

# Synthesis and Antimicrobial Properties of New Derivatives of Morpholine and Piperidine Based on 1-Chloro-3-methoxy-propylbenzene

G.Sh. Duruskari<sup>1,\*</sup>, M.N. Maharramov<sup>1</sup>, U.Sh. Hasanova<sup>1</sup>, Kh.G. Ganbarov<sup>2</sup>, G.M. Eyvazova<sup>1</sup>, A.A. Israyilova<sup>2</sup> and A.M. Maharramov<sup>1</sup>

<sup>1</sup>Department of Organic Chemistry, Baku State University, Z. Khalilov Str. 23, Baku, Azerbaijan <sup>2</sup>Department of Microbiology, Baku State University, Z. Khalilov Str. 23, Baku, Azerbaijan

\*Corresponding author: Tel: +994 503459245; E-mail: gduruskari@mail.ru

Received: 19 June 2017;	Accepted: 14 September 2017;	Published online: 31 December 2017;	AJC-18690

The compounds 1-(3-methoxy-1-phenyl-propyl)morpholine and 1-(3-methoxy-1-phenyl-propyl)piperidine have been synthesized using (3-methoxy-propenyl)benzene and 1-chloro-3-methoxy-propylbenzene. The structures of the synthesized compounds were analyzed by NMR and IR spectroscopic methods. Biological activities of obtained products were investigated against Gram-negative and Gram-positive microorganisms. It has been showed that all the synthesized compounds possess pronounced antimicrobial activity against pathogenic bacteria *Acinetobacter baumannii* BDU32, *Escherichia coli* BDU12, *Klebsiella pneumoniae* BDU44, *Pseudomonas aeruginosa* BDU49 and *Staphylococcus aureus* BDU23.

Keywords: Ethylbenzene, Ether, Morpholine, Piperidine, Antibacterial activity, Pathogenic bacteria.

# **INTRODUCTION**

Arene derivatives containing functionally substituted amine fragment in side chain shows the high biological activity. These compounds reveal activity as antiectoparasitic [1], in inactivation of cytochrome P-450 [2-4], pesticide [5], anti-HIV [6], inhibitor of potassium channels [7], having antidepressant activity [8] ligands of calsium receptors [9,10], antihepatit C agent [11], anticancer [12], antihypertensive [13] compounds and at cure of coronary disease [14]. Beside these, this compounds demonstrate high potency for design of new drugs having antimicrobial properties [15-18].

The searching of new antimicrobial agents still remains an important and challenging problem due to rise of mortality and morbidity that caused by different pathogenic bacteria. In addition, the increasing number of multi-drug resistant microbial strain is considered to be one of the major problems in the world nowadays [19]. It is known that 70 % of bacterial infections are resistant to one or more of the antibiotics that generally used to eradicate the infection. Bacteria are able to reduce or eliminate the effectiveness of drugs by different mechanisms such as mutation of their genome, destruction or inactivation and efflux pump system. Therefore, development and synthesis of new effective antimicrobial agents for the treatment of resistant bacterial diseases is an urgent task [20,21]. The design of molecules with antimicrobial properties by means of introduction of amino moiety and methoxy group in the molecule can lead to the purposeful tuning of their chemical properties and hence the biological activity as well. Beside this, aromatic ring is a constituent part of most naturally occurring biologically active compounds and artificially synthesized drugs. The paper reports the synthesis and antimicrobial properties of functionalized substituted amine compounds *viz.*, new derivatives of morpholine and piperidine based on 1-chloro-3-methoxy-propylbenzene.

## **EXPERIMENTAL**

<sup>1</sup>H, <sup>13</sup>C NMR spectra have been taken on the spectrometer Brucker-300 (300 MGz) of system AVANCE, for measure of refract constant used IRF454BM. FTIR spectra were recorded on a Varian 3600 FTIR spectrophotometer. The spectrum was taken in the range of 4000-400 cm<sup>-1</sup> at room temperature. The ethylbenzene, morpholine, piperidine reagents were purchased from Sigma Aldrich 99 %, ethanol 95 %, ZnCl<sub>2</sub> 98 % from PEAXIME.

Synthesis of 1-(chloro-3-methoxy-propenyl)benzene: Chlorodimethyl ether (8 g, 0.1 mol) dissolved in 25 g (0.3 mol) of hexane and then 14 g (0.1 mol) of  $\alpha$ -chloro-ethyl-benzene added drop-wise to solution. 1 g of ZnCl<sub>2</sub> used as catalyst of reaction. The reaction mixture was stirred for 4 h at 60 °C. At the end of reaction the colour of reaction mixture turned black. The hexane was distilled off and residue was dissolved in benzene. Obtained mixture washed with water till neutral reaction several times, then benzene was distilled *in vacuo*. Yield 75 %; m.p.: 72 °C\1 mm  $n_D^{20}$  15160  $d_4^{20}$  10807 DMSO <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>,  $\delta$ , m.d) 2.3 (M, 2H, CH<sub>2</sub>Cl), 3.25 (C, 3H, OCH<sub>3</sub>), 3.42 (M, 2H, CH<sub>2</sub>O), 5.21 (m, 1H, 7.33 (m, 5H, arom.). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>,  $\delta$ , m.d) 39.5 (C, CH<sub>2</sub>Cl), 58.5 (C, OCH<sub>3</sub>), 60.9 (C, CH), 69.2 (C, CH<sub>2</sub>O), 127.4 (2C, CH<sub>arom</sub>, 128.7 (C, CH<sub>arom</sub>.), 129.0 (2C, CH<sub>arom</sub>). IR (cm<sup>-1</sup>): 3064-2927 (C-H Ar), 1600-1454 (C-C Ar), 1120-705 (C-H<sub>(d)</sub> Ar), 760, 698 (C-Cl), 2828 (OCH<sub>3</sub>). Anal. Calc. for C<sub>10</sub>H<sub>13</sub>ClO, % C 65, 041, H 7, 096, Cl 19, 198. Found: C 65.01, H 6.998, Cl 19.09.

Synthesis of 1-(3-methoxy-1-phenyl-propyl)morpholines (I): 1-(Chloro-3-methoxy-propenyl)benzene (6 g, 0.03 mol) was added drop-wise to 30 g (0.3 mol) morpholine and reaction mixture was stirred for 4 h at 100 °C. C<sub>2</sub>H<sub>5</sub>OH and KOH was added to reaction mixture and then extracted with benzene and washed with water until neutral media. Organic layer was separated, washed and distillated. Yield 68.30 %. m.p.: 122 °C DMSO <sup>1</sup>H NMR spectra: (DMSO-*d*<sub>6</sub>, δ, m.d, ), 1.81-2.22 (m-m, 2H, CH<sub>2</sub>), 2.28 (d, 4H, 2CH<sub>2</sub>N), 3.08 (t, 2H, C 3.11 (S, 3H, CH<sub>3</sub>O), 3, 42 (t, 1H, CHN), 3.53 (t, 4H, 2CH<sub>2</sub>O), 7.19-7.37 (m, 5H, Ar). IR (cm<sup>-1</sup>) 3060-2955 (C-H Ar), 1600-1492 (C-C Ar), 1110-705 (C-H<sub>(d)</sub> Ar), 3500-3450 (NH), 2808 (OCH<sub>3</sub>), 2960-2910 (C-H<sub>s</sub> alif) 1500-1350 (C-H<sub>(d)</sub> alif), 1452 (CH<sub>2(d)</sub>), 1328, 1186, 567 (morpholine's ether group). Anal. Calc. for C<sub>14</sub>H<sub>21</sub>NO<sub>2</sub>(I) % C 71, 455; H 8, 995, N 5, 952. Found: C 71.35, H 8.91, N 5.78.

Synthesis of 1-3-methoxy-1-phenylpropyl-piperidine (**II**) was carried out by similar protocol. Yield 71.2 %; m.p.: 85 °C, DMSO <sup>1</sup>H NMR spectra (DMSO- $d_6$ ,  $\delta$ , m.d, ), 1.23 (m, 2H, CH<sub>2</sub>), 1.40 (m, 4H, 2CH<sub>2</sub>), 1.85-2.17 (m-m, 2H, CH<sub>2</sub>), 2.26 (t, 4H, 2CH<sub>2</sub>N), 3.11 (s, 3H, CH<sub>3</sub>O), 3.24 (t, 2H, CH<sub>2</sub>O), 3.48 (t, 1H, CHN), 7.15-7.31 (m, 5H, Ar). <sup>13</sup>C NMR spectra (DMSO- $d_6$ ,  $\delta$ , m.d, ), 24.83, 26.40, 32.00, 50.77, 58.28, 6.38, 70.07, 127.27, 128.18, 128.83, 139.29. IR (cm<sup>-1</sup>) 3060-2931 (C-H Ar), 1451-1600 (C-C Ar), 1118-702 (C-H<sub>(d)</sub> Ar), 3447 (NH), 2852-2803 (OCH<sub>3</sub>), 1491-1358 (C-H<sub>(d)</sub> alif), 2752 (piperidine band). Anal. Calc. for C<sub>15</sub>H<sub>23</sub>NO (II) %: C 7, 205, H 9, 935, N 6, 002 Found: C 7.00, H 9.91, N 5.99.


Synthesis of (3-methoxy-prop-1-en-1-yl)benzene (III): Synthesis of compound (3-methoxy-prop-1-en-1-yl)benzene, was carried out by dehydrochlorination of initial compound 1-(chloro-3-methoxy-propyl)benzene. Dehydrochlorination was carried out at 110 °C for 1.5 h by using potassium diethylglycolate. <sup>1</sup>H NMR spectra: Yield 78 %; m.p.: 120 °C, DMSO <sup>1</sup>H NMR (DMSO- $d_6$ ,  $\delta$ , m.d), 3.27 (S, 3H, CH<sub>3</sub>O), 4.00-4.02(dd, 2H, CH<sub>2</sub>O), 6.33 (m, 1H, CH), 6.58 (d, 1H, CH), 7.23-7.44 (m, 5H, Ar). <sup>13</sup>C NMR spectra (DMSO- $d_6$ ,  $\delta$ , m.d), 57.74, 72.63, 126.74, 126.85, 128.02, 129.04, 131.72, 136.87. IR (cm<sup>-1</sup>): 3060-2925 (C-H Ar), 1450-1600 (C-C Ar), 2820-2815 (OCH<sub>3</sub>), 1600-1520 (C C). Anal. Calc. for C<sub>10</sub>H<sub>12</sub>O (III) %:C 81, 043, H 8, 161 Found: C 80.98, H 8.06

Determination of antibacterial activity: All the synthesized compounds were screened for their antibacterial activities against Acinetobacter baumannii BDU32, Gram-negative bacteria Eschericha coli BDU12, Klebsiella pneumoniae BDU44, *Pseudomonas aeruginosa* BDU49, Gram-positive bacterium *Staphylococcus aureus* BDU23 using agar well diffusion method [22,23]. The cultures of microorganisms were grown in autoclaved Muller-Hinton media and 0.5 McFarland bacterial culture ( $1.5 \times 10^8$  cfu/mL) were swabbed on the agar plate. The 8 mm wells were made in the center of the plate with a sterile cork borer. Each wells filled with the two different concentrations (0.1 %, 0.05 %) of compounds, which were solved in the ethanol and solvent is used as a control during investigation. The antimicrobial activities were determined by measuring the diameter of the complete inhibition (mm) zones of compounds after incubation of plates at 37 °C for 24 h. The standard error for the experiment was ± 0.001 cm and the antibacterial investigation was repeated three times under same condition.

#### **RESULTS AND DISCUSSION**


For the purposeful synthesis of benzene derivative, that contain methoxy group and amine fragment in side chain we carried out the reaction of halogen ethers of aromatic compounds with morpholine and piperidine. Compounds with amine functional group can be obtained by three main ways: alkylation of amines, hydrogenolysis of amides and reductive amination of carbonyl compounds. It is known that the presence of methoxy group in the molecules allow to obtain the biologically active compounds which being insensitive to esterases are resistant to the hydrolysis that in turn increase their retention time in the cell [24].

The synthesis of 1-(3-methoxy-1-phenylpropyl)piperidine and 1-(3-methoxy-1-phenyl-propyl)morpholine have been taken from initial 1-(chloro-3-methoxy-propenyl)benzene, which was obtained by reaction of 1-chloroethylbenzene with chlorodimethyl ether in the presence of zinc chloride catalyst. We studied the molar concentration ratio of reagents on the course of reaction. It was found that carrying out the reaction at 40-60 °C and equimolar amount of zinc chloride and chlorodimethyl ether leads to obtaining of the product of reaction 1-(chloro-3-methoxy-propyl)benzene with 90 % yield. The reaction begins by the attack of zinc chloride on chlorodimethyl ether and then continues as shown in **Scheme-I**.



Scheme-I: Attack of zinc chloride on chlorodimethyl ether

It is known that in benzyl chloride molecule, chlorine atom undergoes nucleophile replacement, which can be explained by the stability of formed benzyl carbocation and by small steric hindrance of chlorine atom. That is why this compound is most traditional agent in benzylation of organic compound. Aniline, diethylamine and some other nucleophile reagents are not able to react with 1-chloroethylbenzene, due to the fact that reaction centers are shielded in a great extent in opposite to piperidine, morpholine. So we use piperidine and morpholine as nucleophiles in the alkylation of preliminarily synthesized 1-(chloro-3-methoxy-propenyl)benzene. It was also interesting to find out the effectiveness of 1-(chloro-3-methoxy-propyl)benzene in synthesis of (3-methoxy-prop-1-en-1-yl)benzene by dehydrochlorination in the presence of sodium ethylate. This reactions are presented in **Scheme-II**.



Scheme-II: Reactions of 1-(chloro-3-methoxy-propenyl)benzene

Physico-chemical data of the synthesized compounds presented in Table-1. Have been reported about the bioconversion of tetrahydropyridines with some strains of the mycellar fungi [25]. Antimicrobial properties of morpholine and piperidine derivatives obtained from the substitution reaction of  $\alpha$ -chloroethers of propylbenzene are not reported in literature. For finding out the correlation structure-activity, we introduce the morpholine and piperidine moieties by substitution of the chlorine atom in 1-chloro-(3-metoxy-propyl)benzene. The presence of piperidine and morpholine groups provide effective antimicrobial properties of synthesized compounds. Antibacterial studies of the synthesized compounds: In vitro antibacterial study was carried out for all new synthesized arene derivatives compounds. It revealed that all chemical compounds possessed antibacterial activity against tested Gram-positive and Gram-negative bacteria. All compounds exhibited potential inhibition activity and the clear zones around wells inhibited the bacterial growth were determined as shown in Table-2. The antimicrobial effect of molecules was different not only depending on the species of bacteria but also concentration of tested compounds.

Compound **1** [1-(3-methoxy-1-phenyl-propyl)morpholine] at the concentration of 0.1 % showed better result when tested with the *A. baumannii* BDU32 and *P. aeruginosa* BDU49, while at the concentration of 0.05 % inhibition zones were similar for all studied pathogens except *K. pneumoniae* BDU 44.

The bacterial activity results revealed that compound **2** [1-(3-methoxy-1-phenyl-propyl)piperidine] at two concentrations, showed potential activity against all tested pathogenic bacteria except *S. aureus* BDU23. Compare with other two chemicals, compound **2** showed high activity against *P. aeruginosa* BDU49, while any inhibition was not detected against *E. coli* BDU12 when the effect of the compound was tested at concentration of 0.05 %.

The high inhibition zones were detected against *E. coli* BDU12 and *A. baumannii* BDU32 at the concentration of 0.1 % of compound III (3-methoxy-propenyl)benzene, whereas chemical exhibited the lowest activity when tested with *S. aureus* BDU23 and *P. aeruginosa* BDU49 at the concentration of 0.05 %. From the results, it is clear that all the new synthesized compounds have sufficiently activity against all tested Gram-negative bacteria, only Gram-positive bacterium *S. aureus* BDU23 are less sensitive.

		AN	TIBACTERIAL RE	TABLE-1 SULTS OF ARENE I	DERIVATIVES				
		Cama	Antibacterial activity (zone of inhibition in mm)						
Number	Compound	Conc (%)	Acinetobacter baumannii	Escherichia coli	Klebsiella pneumoniae	Pseudomonas aeruginosa	Staphylococcus aureus		
I	HC N O	0.10 0.05	16 10	14 12	10 8	15 11	13 12		
п	CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub> HC N	0.10 0.05	16 14	12 0,0	13 11	20 19	0,0 0,0		
Ш	CHCH <sub>2</sub> OCH <sub>3</sub>	0.10 0.05	16 11	15 13	10 14	12 7	9 8		
IV	Control ethanol (95 %)		5	4	4	4	4		

TABLE-2 PHYSICAL-CHEMICAL DATA OF SYNTHESIZED COMPOUNDS							
Compound	m.p. (°C/1 mm)	$d_4^{20}$	n4 <sup>20</sup>	MR <sub>D</sub>	Calculated		
HC N O	122	1.0369	1.5180	68.68	68.30		
HC N	85	0.9869	1.5350	46.60	46.00		
CHCH <sub>2</sub> OCH <sub>3</sub>	120	0.9914	1.5150	70.84	71.20		

-----

## Conclusion

We reported synthesis of morpholine and piperidine derivatives of aromatic compounds containing  $\beta$ -methoxy group in side chain with good yield. The structures of the synthesized compounds were identified by NMR and IR spectroscopy methods. It was found that introduction of morpholine and piperidine fragments in the structures of molecules influence on their antimicrobial activities. All compounds exhibited potential inhibition activity against Gram-positive and Gramnegative bacteria.

## REFERENCES

- P. Ducray, T. Cavaliero, M. Lohrmann and J. Bouvier, Preparation of β-Amino Alcohol Derivative Ectoparasiticides and Ectoparasite Repellents, PCT Int. Appl. WO 2008062006 A1 (2008).
- J. Chun, U.M. Kent, R.M. Moss, L.M. Sayre and P.F. Hollenberg, *Drug Metab. Dispos.*, 28, 905 (2000).
- K. Korzekwa, D. Tweedie, U.A. Argikar, A. Whitcher-Johnstone, L. Bell, S. Bickford and S. Nagar, *Drug Metab. Dispos.*, 42, 1587 (2014); <u>https://doi.org/10.1124/dmd.114.058297</u>.
- L.C. Blake, N.D. Roy, D. Neul, F.J. Schoenen, J. Aubé and E.E. Scott, *Pharm. Res.*, **30**, 2290 (2013);
- https://doi.org/10.1007/s11095-013-1054-z.
- S. Schnatterer, M. Maier, F. Petry, W. Knauf and K. Seeger, Pesticidal Substituted Piperidines, US Patent 20090082389 A1 (2009).
- G.V. Grishina, A.A. Borisenko, Z.G. Nosan', I.S. Veselov, L.D. Ashkinadze, E.V. Karamov, G.V. Kornilaeva and N.S. Zefirov, *Dokl. Chem.*, **391**, 195 (2003);
- https://doi.org/10.1023/A:1025307617288.
- D.C. Beshore, N.J. Liverton, C.J. McIntyre, C.F. Claiborne, B. Libby, J.C. Culberson, J.J. Salata, C.P. Regan, J.J. Lynch, L. Kiss, R.H. Spencer, S.A. Kane, R.B. White, S. Yeh, G.D. Hartman and C.J. Dinsmore, *Bioorg. Med. Chem. Lett.*, 20, 2493 (2010); https://doi.org/10.1016/j.bmcl.2010.03.005.
- 8. J. Li, Y. Zheng, Y. Liao and Y. Li, PCT Int. Appl. WO 2011140998 A1 (2011).
- W. Van, C. Bradford, S.T. Moe, M.F. Balandrin, E.G. Delmar and E.F. Nemeth, Calcium Receptor-Active Compounds, U.S. Patent 6211244 B1 (2001).

- M.G. Kelly, S. Xu, N. Xi, P. Miller, J.F. Kincaid, C. Ghiron and T. Coulter, PCT Int. Appl. WO 2003099776 A1 (2003).
- S. He, J. Xiao, A.E. Dulcey, B. Lin, A. Rolt, Z. Hu, X. Hu, A.Q. Wang, X. Xu, N. Southall, M. Ferrer, W. Zheng, T.J. Liang and J.J. Marugan, *J. Med. Chem.*, **59**, 841 (2016); <u>https://doi.org/10.1021/acs.jmedchem.5b00752</u>.
- 12. K. Li, W. Zhang, J. Lu, Y. Zhou, J. Yang and W. Wan, *Yao Xue Xue Bao*, **31**, 925 (1996).
- 13. J. Xu, L. Xia, P. Ni and J. Fu, Zhongguo Yaoke Daxue Xuebao, 28, 317 (1997).
- K. Tasken, B. Lygren, E. Oestensen and J. Klaveness, PCT Int. Appl, WO 2013171332 A2 (2013).
- P.A. Carter, S.J. Tapp and N.J. Daniels, Eur. Pat. Appl. EP 494717 A1 (1992).
- Y. Kawazu, T. Suzuki, M. Yuasa, Y. Yokomizo, T. Majima, T. Ito, T. Nakashima and A. Nozawa, Antifungal Agents, US Patent 6015925 A (2000).
- T.H. Krane Thvedt, K. Kaasa, E. Sundby, C. Charnock and B.H. Hoff, *Eur. J. Med. Chem.*, 68, 482 (2013);
- https://doi.org/10.1016/j.ejmech.2013.07.043.
- Í. Neto, J. Andrade, A.S. Fernandes, C.P. Reis, J.K. Salunke, A. Priimagi, N.R. Candeias and P. Rijo, *ChemMedChem*, **11**, 2015 (2016); <u>https://doi.org/10.1002/cmdc.201600244</u>.
- C.A. Lipinski, Drug Discov. Technol., 1, 337 (2004); https://doi.org/10.1016/j.ddtec.2004.11.007.
- M.J. Macielaq, eds.: T.J. Dougherty and M.J. Pucci, Chemical Properties of Antibacterials and their Uniqueness, In: Antibiotic Discovery and Development, pp. 801-802 (2012).
- A. Israyilova, S. Buroni, F. Forneris, V.C. Scoffone, N.Q. Shixaliyev, G. Riccardi and L.R. Chiarelli, *PLoS One*, **11**, e0167350 (2016); <u>https://doi.org/10.1371/journal.pone.0167350</u>.
- A.U. Rahman, M.I. Choudhary and W.J. Thomson, Bioassay Techniques for Drug Development, Harwood Academic Publishers, Netherland (2001).
- V. Tirkey, S. Mishra, H.R. Dash, S. Das, B.P. Nayak, S.M. Mobin and S. Chatterjee, J. Organomet. Chem., 732, 122 (2013); https://doi.org/10.1016/j.jorganchem.2013.02.020.
- D. Belmessieri, C. Gozlan, M. Duclos, V. Molinier, O. Dumitrescu, J. Aubry, G. Lina, A. Redl, N. Duguet and M. Lemaire, *J. Med. Chem.*, **128**, 98 (2017);

https://doi.org/10.1016/j.ejmech.2017.01.038.

 P.B. Terentiev, T.M. Zilberstein, A.A. Borisenko, V.A. Shmorgunov, N.F. Piskunkova and G.V. Grishina, *Chem. Heterocycl. Compd.*, **39**, 885 (2003); <u>https://doi.org/10.1023/A:1026142220384</u>.